Main Article Content

Impact of Sodium Bicarbonate Supplementation on Serum Alpha Klotho in Chronic Kidney Disease Patients


Howayda A. Elshinnawy
Lina Essam Khedr
Mahmoud Rabie Ibrahim
Marwa Shaban Abdel Samea

Abstract

Background: The course of chronic kidney disease (CKD) is highly connected with the Klotho gene through multiple pathways, including  renal fibrosis, vascular calcification, inflammation, and mineral bone abnormalities.


Objectives: This study aimed to assess the impact of  oral sodium bicarbonate supplementation on blood levels of soluble α-Klotho in patients suffering from chronic renal disease (stage 3b:4)  at Ain Shams Specialized Hospital in Cairo, Egypt, using the CKD-EPI formula.


Patients and Methods: 45 CKD patients were recruited  for this interventional, prospective, open-label clinical trial from the Inpatient and Outpatient Clinics at Ain Shams Specialized Hospital in  Cairo, Egypt.


Results: The cohort study had an average age of 48.13 ± 6.96 years. Serum bicarbonate (HCO3) improved from mean 19.74 ±  1.43 mmol/L pre-study to 23.63 ± 3.23 mmol/L post-study, with a p-value of 0.000. Additionally, eGFR significantly improved with a p- value of 0.000 following the study. Serum alpha Klotho level was 596.30 ± 148.58 pg/mL before the study and 696.16 ± 172.99 pg/mL after  the study, with a statistically significant difference of 0.006. Serum alpha Klotho after the study did not show a statistically significant link  with serum creatinine, eGFR, potassium and phosphorus, or parathyroid. However, serum bicarbonate level and serum Klotho after the  study showed a statistically significant positive correlation.


Conclusion: Serum soluble α klotho level was significantly higher post-study  compared to pre-study after oral sodium bicarbonate supplementation and improved acidosis. 


Journal Identifiers


eISSN: 2090-7125
print ISSN: 1687-2002